The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

A method of treating soil, the method comprising providing the soil with a glucosinolate-secreting plant or a source thereof and contacting said soil with a myrosinase-secreting yeast of the x or a source thereof.

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

The present disclosure relates to a pharmaceutical composition for improving and treating leukotrichia and/or alopecia and a preparation method thereof. In the present disclosure, the pharmaceutical composition includes glucoraphanin and myrosinase as active ingredients, where the glucoraphanin has a content of 0.1% to 50% and the myrosinase has a total enzyme activity of 0.1 mU to 10 U based on a total weight of the pharmaceutical composition. The pharmaceutical composition shows safety, rapidity, effective improvement and treatment of leukotrichia and/or alopecia, and wide application range for subjects.

A pest protective apparatus adapted for controlling plant pathogens. The pest protective apparatus comprises at least one fibrous network and/or at least one fibrous cover. The pest protective apparatus is remarkable in that the at least one fibrous network and/or the at least one fibrous cover comprises a system in which at least one precursor is transformed into a biopesticide and/or repellent product.

A preparation able to produce a biopesticide and/or repellent for controlling plant pathogens, comprising at least one nanoporous material and at least one active enzyme, the at least one active enzyme being configured to transform at least one precursor into a biopesticide and/or repellent product. The preparation able to produce a biopesticide and/or repellent for controlling plant pathogens is remarkable in that the at least one active enzyme is immobilized within the at least one nanoporous material.

Disclosed is a formulation which contains microcapsules which contain a core containing an extract rich in glucosinolates obtained from crucifers and a biopolymer, and an enteric coating containing myrosinase and a biopolymer. Also, disclosed is a procedure for obtaining the same and to a use of the formulation as such, or in dietetic food supplements for humans or animals due to its immunostimulant activity.

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a -glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.